Skip to main
CBLL

Ceribell Inc (CBLL) Stock Forecast & Price Target

Ceribell Inc (CBLL) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CeriBell Inc. is projecting a revenue increase to $87M-$89M in 2025, reflecting a year-over-year growth of 33%-36%, which indicates substantial commercial traction despite being in the early stages of its product rollout. The company is strategically investing in its salesforce and product pipeline, with plans to expand into new hospital markets and additional patient demographics, which underscores a long growth runway. Furthermore, with gross margins optimized in the mid-80% range, CeriBell is positioned to enhance profitability through operational leverage as it scales its operations.

Bears say

CeriBell Inc. is experiencing significant financial challenges, exemplified by a net loss of $40 million and a lack of positive free cash flow, which raises concerns about its sustainability in the medical technology sector. The company faces pressing margin headwinds due to increasing tariffs on imports from China and associated legal expenses, which could further degrade its gross margins and necessitate a shift in sourcing strategies. Additionally, the combination of geopolitical risks, supply chain vulnerabilities, and low market penetration heightens the overall risk profile of the company, contributing to a negative outlook on its stock performance.

Ceribell Inc (CBLL) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ceribell Inc (CBLL) Forecast

Analysts have given Ceribell Inc (CBLL) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Ceribell Inc (CBLL) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ceribell Inc (CBLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.